SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).

Clin Transl Oncol · 2019 · PMC6339680 · PMID 30446985

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Combinations of bevacizumab and erlotinib were also explored in the first-line setting demonstrating a significant increase in PFS but only a slight trend of OS improvement with the combination [ 71 – 73 ] (I,B).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.